Company Profile

LKC Technologies Inc
Profile last edited on: 1/5/16      CAGE: 00QR2      UEI: HLUEBPPQSJN9

Business Identifier: Diabetic retinopathy screening; visual electrophysiology diagnostic products
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2 Professional Drive Suite 222
Gaithersburg, MD 20879
   (301) 840-1992
Location: Single
Congr. District: 06
County: Montgomery

Public Profile

LKC Technologies Inc is a biotechnology and medical device company primarily focused in the visual electrophysiology field. The firm has created a low-priced, handheld diabetic retinopathy (DR) screening device, called RETeval, to enable virtually any health care provider to screen for and detect sight-threatening DR, the leading cause of working age blindness worldwide. RETeval is a functional test of the retina to assess the ischemic level of the retina, which correlates well to DR and other ischemic diseases such as Central Retinal Vein Occlusion, Birdshot and others. The low price allows health care providers, from physicians' offices to community clinics to mobile clinics in third-world countries, to easily use the RETeval and be highly effective in alerting patients to their risk of diabetic retinopathy. The Centers for Disease Control estimates that better DR detection can reduce blindness by 50-60%.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 2 NIH $1,349,545
Project Title: Screening Device for Diabetic Retinopathy
1989 2 NIH $550,000
Project Title: Electroretinographic test to monitor retinal ischemia
1989 1 NIH $50,000
Project Title: Objective measurement of the optical quality of the eye
1986 2 NIH $350,000
Project Title: Discrimination test for early galucoma detection

Key People / Management

  James J Datovech -- President

  Frank Chen

  James Datovech

  Quentin Davis -- Vice President of Operations

  Sigmund Krassowsky

  Jerome Leight

  Matthew L Severns -- Chief Operations Officer

Company News

There are no news available.